CANbridge Pharmaceuticals Inc. (HK:1228)
:1228
Want to see HK:1228 full AI Analyst Report?
Top Page
CANbridge Pharmaceuticals Inc.
(1228)
Select Model
Select Model
Rating:42Neutral
Price Target:
HK$2.00
▼(-20.63% Downside)
Action:Upgraded
Date:05/30/26
The score is held down primarily by weak financial quality (negative equity, persistent operating losses, and continued cash burn). Technicals also point to a strong downtrend, while valuation provides limited support given the high P/E and no dividend yield data.
Positive Factors
Specialty / Rare-disease Focus
A focused rare-disease and specialty-medicine strategy creates durable demand and higher barriers to entry, supporting premium pricing, long product lifecycles, and partnership opportunities. This niche orientation underpins sustained commercial and licensing potential over months.
Negative Factors
Negative Shareholders' Equity
Persistently negative equity reflects cumulative losses and weak capital buffers, restricting access to some financing channels and increasing governance and creditor scrutiny. This fragile capital structure materially limits long-term financial flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Specialty / Rare-disease Focus
A focused rare-disease and specialty-medicine strategy creates durable demand and higher barriers to entry, supporting premium pricing, long product lifecycles, and partnership opportunities. This niche orientation underpins sustained commercial and licensing potential over months.
Read all positive factors
CANbridge Pharmaceuticals Inc. (1228) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.19B
Dividend YieldN/A
Average Volume (3M)5.03M
Price to Earnings (P/E)54.7
Beta (1Y)1.17
Revenue Growth-41.19%
EPS GrowthN/A
CountryHK
Employees67
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.32
Shares Outstanding595,443,360
10 Day Avg. Volume2,153,700
30 Day Avg. Volume5,027,972
Financial Highlights & Ratios
PEG Ratio-0.75
Price to Book (P/B)-3.32
Price to Sales (P/S)22.72
P/FCF Ratio-29.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.67
Revenue Forecast (FY)HK$299.65M
CANbridge Pharmaceuticals Inc. Business Overview & Revenue Model
Company Description
CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy...
How the Company Makes Money
CANbridge’s revenue model is centered on monetizing a portfolio of specialty/rare-disease therapeutics through commercialization and partnering. Key potential revenue streams include: (1) Product sales revenue from commercialized medicines (where ...
CANbridge Pharmaceuticals Inc. Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 62.56M | 49.98M | 85.10M | 102.87M | 78.97M | 31.16M |
| Gross Profit | 40.29M | 36.55M | 54.30M | 64.16M | 48.89M | 18.78M |
| EBITDA | -150.16M | -78.98M | -328.69M | -341.43M | -454.63M | -1.06B |
| Net Income | -136.11M | 14.82M | -442.62M | -378.84M | -483.48M | -1.08B |
Balance Sheet | ||||||
| Total Assets | 105.50M | 165.46M | 116.81M | 395.36M | 702.04M | 892.52M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 66.65M | 10.50M | 137.49M | 451.16M | 745.82M |
| Total Debt | 34.97M | 16.09M | 135.78M | 141.93M | 155.28M | 52.10M |
| Total Liabilities | 514.58M | 507.36M | 591.30M | 435.15M | 393.49M | 199.13M |
| Stockholders Equity | -409.08M | -341.90M | -474.49M | -39.79M | 308.56M | 693.39M |
Cash Flow | ||||||
| Free Cash Flow | -14.19M | -38.22M | -122.50M | -319.09M | -315.76M | -592.40M |
| Operating Cash Flow | -14.10M | -38.21M | -122.39M | -278.23M | -280.98M | -587.07M |
| Investing Cash Flow | -38.00K | 1.23M | 13.93M | -26.86M | -34.79M | 126.09M |
| Financing Cash Flow | 0.00 | 92.47M | -18.57M | -28.02M | -20.70M | 854.31M |
CANbridge Pharmaceuticals Inc. Technical Analysis
Negative
2.52
Price Trends
2.32
Negative
2.48
Negative
2.36
Negative
Market Momentum
-0.09
Negative
44.14
Neutral
58.85
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1228, the sentiment is Negative. The current price of 2.52 is above the 20-day moving average (MA) of 2.06, above the 50-day MA of 2.32, and above the 200-day MA of 2.36, indicating a bearish trend. The MACD of -0.09 indicates Negative momentum. The RSI at 44.14 is Neutral, neither overbought nor oversold. The STOCH value of 58.85 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1228.
CANbridge Pharmaceuticals Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$32.66B | 34.76 | 23.99% | ― | 16.65% | 0.87% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$10.00B | -79.57 | -11.81% | ― | 219.26% | 87.63% | |
48 Neutral | HK$6.97B | -51.62 | -6.26% | ― | -11.65% | -169.40% | |
45 Neutral | HK$3.24B | -19.16 | -17.64% | ― | -65.87% | 6.71% | |
42 Neutral | HK$1.19B | 54.74 | 9.41% | ― | -41.19% | ― | |
42 Neutral | HK$31.98B | -46.76 | -10.78% | ― | 34.19% | 47.97% |
* Healthcare Sector Average
HK:1228
CANbridge Pharmaceuticals Inc.
1.98
1.83
1220.00%
HK:9966
Alphamab Oncology
6.95
-1.02
-12.80%
HK:1167
Jacobio Pharmaceuticals Group Co., Ltd.
4.14
-0.97
-18.98%
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
17.26
-4.09
-19.16%
HK:2171
CARsgen Therapeutics Holdings Ltd.
16.32
-2.88
-15.00%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
60.20
14.60
32.02%
CANbridge Pharmaceuticals Inc. Corporate Events
CANbridge Ties CEO Equity Award to Licensing Milestones and Sales Growth
Apr 12, 2026
CANbridge Pharmaceuticals has proposed granting 6,372,574 share options and an equal number of restricted share units to its chairman and chief executive officer, Dr. Xue, under its post-IPO incentive schemes, pending independent shareholder appro...
CANbridge Reshuffles Key Company Secretary and Compliance Roles After Resignation
Mar 31, 2026
CANbridge Pharmaceuticals announced that joint company secretary, authorised representative and Hong Kong process agent, Mr. Wai Chiu Wong, has resigned from all his roles with effect from March 30, 2026, citing no disagreement with the board or i...
CANbridge deepens Baheal alliance as rare-disease drugs gain regulatory and insurance momentum in China
Mar 30, 2026
CANbridge reported strong operational progress in 2025, driven by a strategic cooperation with Baheal Medical that designates Baheal’s subsidiaries as exclusive contract sales organizations and potential distributors for Hunterase, Livmarli ...
CANbridge Pharmaceuticals Schedules Board Meeting to Approve 2025 Annual Results
Mar 18, 2026
CANbridge Pharmaceuticals Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual results for the year ended December 31, 2025 and to authorize their publication. The announcement signals the forthcoming release of f...
CANbridge Flags WuXi License Deals as Connected Transactions After New Major Shareholder Entry
Mar 10, 2026
CANbridge Pharmaceuticals has disclosed that, following completion of a recent share subscription, the subscriber has become a substantial shareholder and connected person under Hong Kong listing rules, bringing affiliate WuXi Biologics Licensor i...
CANbridge Completes HK$2.38 New Share Subscription, Reshaping Shareholder Base
Mar 10, 2026
CANbridge Pharmaceuticals has completed a share subscription under its general mandate, issuing 84,033,613 new shares at HK$2.38 each to a single subscriber. The transaction increases the company’s total issued share capital from 511,409,734...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.